Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer.
Talbot
D C
DC
ICRF Medical Oncology Unit, Churchill Hospital, Oxford, UK.
Brown
P D
PD
D000328:Adult; D000368:Aged; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001201:Ascites / Q000188:drug therapy; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D005109:Extracellular Matrix / Q000201:enzymology*; D005260:Female; D006801:Humans; D008297:Male; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors*; D051379:Mice; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D010649:Phenylalanine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D016066:Pleural Effusion, Malignant / Q000188:drug therapy; D011480:Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use
D000970:Antineoplastic Agents; D011480:Protease Inhibitors; D013876:Thiophenes; D010649:Phenylalanine; C080985:batimastat; D008666:Metalloendopeptidases